Some great suggestions for BBB -- balanced biotech baskets -- are being thrown at the thread. Thanks, all.
RGEN, as might be expected, caught wider attention today..... up 20% and closing on the bid.
Market commentary.......
OK, we've discussed the huge discrepancy between the first- and second-tiers and the mini/micro caps. Since then, there has been a brutal correction in certain "haves". Today, GENZ got clocked, and broke through anything that resembled support. The top tiers have taken rolling hits, and the discrepancy in capitalizations has narrowed a bit.
I regard this as good..... when the "haves" recover, the "have nots" should schlep along a bit. Those of us who pick developmental stage companies should profit, long term, for rational valuations across the sector.
Seems to me, as an aside, that...... if GENZ takes a hit due to questions regarding the pipe, that those tracking stocks with a good promise:pipe ratio should not get hit. And yet GZMO and GZTC were socked by association today. |
